MENTZER INDEX IN EARLY BREAST CANCER: A LOW-COST DIAGNOSTIC INSIGHT INTO ANEMIA PATTERNS
Keywords:
Anemia, breast cancer, early detection, hematological markers, Mentzer indexAbstract
Anemia continues to be one of the most common and overlooked complications in early breast cancer, caused by inflammation related to tumors, iron storage, and treatment-induced suppression of the bone marrow. Determining the root cause of anemia is essential for enhancing treatment and improving patient results. This review examines the potential diagnostic significance of the Mentzer index a ratio of mean corpuscular volume to red blood cell count as a straightforward, affordable method for distinguishing anemia patterns in early breast cancer. Historically utilized to differentiate iron deficiency anemia from thalassemia trait, recent findings indicate that MI might also represent the erythropoietic and inflammatory changes linked to malignancy. A narrative review method was utilized, consolidating existing literature (2015–2024) regarding the mechanisms of anemia in breast cancer, red blood cell indices, and biomarkers for iron metabolism. Research from PubMed, Scopus, and Google Scholar was evaluated to investigate the diagnostic and pathophysiological connections between the Mentzer index and anemia associated with cancer. Results show that increased MI values in early breast cancer frequently relate to functional iron deficiency due to hepcidin-induced iron blockage and inflammation-related suppression of erythropoiesis. On the other hand, low or normal MI levels might indicate mixed or nutritional anemia conditions. Incorporating MI with biomarkers like ferritin, transferrin saturation, and red cell distribution width improves diagnostic accuracy, especially in resource-constrained environments. The Mentzer index, while rooted in tradition, could offer a significant hematologic insight into anemia types in early breast cancer, enabling personalized interventions and enhanced treatment preparedness.
Peer Review History:
Received 4 December 2025; Reviewed 11 January 2026; Accepted 13 February; Available online 15 March 2026
Academic Editor: Dr. Tamer Elhabibi
, Suez Canal University, Egypt, tamer_hassan@pharm.suez.edu.eg
Reviewers:
Dr. Taiwo O Elufioye, University of Ibadan, Nigeria, toonitaiwo@yahoo.com
Dr. Tanveer Ahmed Khan, Hajvery University, Lahore, Pakistan, tanveerahmedkhan754@gmail.com
Downloads
Published
How to Cite
Issue
Section
Copyright (c) 2026 Universal Journal of Pharmaceutical Research

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.




.